Clinical Trial

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-01
Trial Details
NCT Number NCT06921850
Lead Sponsor UCB Biopharma SRL
Conditions Hidradenitis Suppurativa
Enrollment 43 participants
Start Date 2025-04-07
Primary Completion 2026-12-21 (estimated)
Study Completion 2029-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31